The American College of Obstetricians and Gynecologists, or ACOG, released new guidance in October 2026 on the use of GLP-1 receptor agonists in women who are planning pregnancy, pregnant, or breastfeeding.
I want to walk you through the key recommendations, because the guidance is not the same at every stage.
Preconception
Pregnancy safety data for GLP-1 medications remain limited.
ACOG advises considering discontinuation 1 to 2 months before conception. Weight regain is common after stopping, so this is also a time to support nutritional adequacy, healthy eating, physical activity and weight monitoring.
Consider assessing vitamin D, vitamin B12 and ferritin status as well.
Pregnancy
ACOG recommends against GLP-1 use during pregnancy, except within a clinical trial.
Human safety data remain insufficient, and animal studies have identified potential fetal growth and developmental concerns.
If pregnancy occurs while taking a GLP-1 medication, treatment should not be continued.
Lactation
This recommendation is more nuanced.
GLP-1 therapy may be considered as part of an individualized postpartum care plan through shared decision-making.
A small human milk study found no detectable semaglutide in breast milk following subcutaneous administration at the measured time points (0, 12 and 24 hours).
There are insufficient data regarding effects on milk volume, milk composition, infant weight gain and long-term infant outcomes.
When treatment is indicated, ACOG suggests considering medications with a shorter half-life and identifies exenatide as a preferred consideration.
Oral GLP-1 formulations should be avoided during breastfeeding.
Infant weight gain should be closely monitored in coordination with the pediatric provider.
ACOG recommends against use when breastfeeding preterm infants or neonates, meaning babies in the first 28 days of life.
A Few Important Takeaways
GLP-1 medications are not considered safe for use during pregnancy. However, ACOG’s new guidance recognizes that postpartum treatment decisions, particularly during lactation, require a more individualized approach.
Importantly, limited evidence of medication transfer into breast milk is not the same as established safety. We still need more research on milk production, infant growth and long-term outcomes.
If you are taking a GLP-1 medication and thinking about pregnancy, or if you are postpartum and considering treatment while breastfeeding, this is a conversation to have with your own clinician, who can help you weigh the available evidence in the context of your health.
With warmth,
Dr. Starr
Source
American College of Obstetricians and Gynecologists. Use of Glucagon-Like Peptide-1 Receptor Agonists in Pregnancy and Lactation. Practice Advisory. October 2026. https://www.acog.org/clinical/guidance/practice-advisory/2026/10/use-of-glucagon-like-peptide-1-receptor-agonists-in-pregnancy-and-lactation/


Leave a Reply